We are live on ! Find out more

518 hedge funds and large institutions have $21.2B invested in Insmed in 2025 Q2 according to their latest regulatory filings, with 131 funds opening new positions, 168 increasing their positions, 188 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

152% more first-time investments, than exits

New positions opened: 131 | Existing positions closed: 52

33% more capital inflows, than outflows

Capital inflows: $3.34B | Capital outflows: $2.51B

17% more funds holding

Funds holding: 443 → 518 (+75)

6% more funds holding in top 10

Funds holding in top 10: 31 → 33 (+2)

11% less repeat investments, than reductions

Existing positions increased: 168 | Existing positions reduced: 188

10.74% less ownership

Funds ownership: 110.29% → 99.54% (-11%)

16% less call options, than puts

Call options by funds: $300M | Put options by funds: $356M

Holders
518
Holders Change
+75
Holders Change %
+16.93%
% of All Funds
6.79%
Holding in Top 10
33
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+6.45%
% of All Funds
0.43%
New
131
Increased
168
Reduced
188
Closed
52
Calls
$300M
Puts
$356M
Net Calls
-$56.3M
Net Calls Change
+$15.7M

INSM Hedge Fund Activity: Q2 2025 in Review

518 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q2 2025, worth a combined $21.2B — up 39% from $15.3B a quarter earlier.

Buyers outnumbered sellers: 131 funds opened new INSM positions and 52 closed out — a net gain of 79 holders — while 168 added to existing stakes and 188 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $710M. The largest seller was BlackRock, cutting an estimated $375M.

  • 518 institutional investors held Insmed (INSM) as of Q2 2025, up from 443 in Q1 2025.
  • Funds reported $21.2B of Insmed stock for Q2 2025, up 39% quarter-over-quarter.
  • 131 funds opened new Insmed positions in Q2 2025 and 52 closed out, a net change of +79 holders.
  • The largest Insmed buyer in Q2 2025 was JP Morgan Chase, an estimated $710M added.
  • The largest Insmed seller in Q2 2025 was BlackRock, an estimated $375M sold.

Based on aggregated 13F filings for Q2 2025.